Covalis Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Covalis Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$582K	–	152
2026 Q1	$582K	Buy	+10,000	New	+$461K	0.04%	104

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Covalis Capital's XENE Position: Q2 2026 in Review

Covalis Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 10,000 shares — an estimated $582K sold.

Covalis Capital first reported a position in XENE in Q1 2026 and held it in 1 quarter. The position peaked at $582K in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Covalis Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Covalis Capital sold 10,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $582K.
Covalis Capital first reported a position in Xenon Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Covalis Capital's Xenon Pharmaceuticals position peaked at $582K in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Covalis Capital's 13F filing for Q2 2026, filed 13 Aug 2026.